Accelerator Mass Spectrometry in Biomedical Dosimetry: Relationship Between Low-Level Exposure and Covalent Binding of Heterocyclic Amine Carcinogens to DNA
Accelerator mass spectrometry (AMS) is used to determine the amount of carcinogen covalently bound to mouse liver DNA (DNA adduct) following very low-level exposure to a14C-labeled carcinogen. AMS is a highly sensitive method for counting long-lived but rare cosmogenic isotopes. While AMS is a tool...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 87; no. 14; pp. 5288 - 5292 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
National Academy of Sciences of the United States of America
01.07.1990
National Acad Sciences |
Subjects | |
Online Access | Get full text |
ISSN | 0027-8424 1091-6490 |
DOI | 10.1073/pnas.87.14.5288 |
Cover
Loading…
Abstract | Accelerator mass spectrometry (AMS) is used to determine the amount of carcinogen covalently bound to mouse liver DNA (DNA adduct) following very low-level exposure to a14C-labeled carcinogen. AMS is a highly sensitive method for counting long-lived but rare cosmogenic isotopes. While AMS is a tool of importance in the earth sciences, it has not been applied in biomedical research. The ability of AMS to assay rare isotope concentrations (10Be,14C,26Al,41Ca, and129I) in microgram amounts suggests that extension to the biomedical sciences is a natural and potentially powerful application of the technology. In this study, the relationship between exposure to low levels of 2-amino-3,8-dimethyl[2-14C]imidazo[4,5-f]quinoxaline and formation of DNA adducts is examined to establish the dynamic range of the technique and the potential sensitivity for biological measurements, as well as to evaluate the relationship between DNA adducts and low-dose carcinogen exposure. Instrument reproducibility in this study is 2%; sensitivity is 1 adduct per 1011nucleotides. Formation of adducts is linearly dependent on dose down to an exposure of 500 ng per kg of body weight. With the present measurements, we demonstrate at least 1 order of magnitude improvement over the best adduct detection sensitivity reported to date and 3-5 orders of magnitude improvement over other methods used for adduct measurement. An additional improvement of 2 orders of magnitude in sensitivity is suggested by preliminary experiments to develop bacterial hosts depleted in radiocarbon. Expanded applications involving human subjects, including clinical applications, are now expected because of the great detection sensitivity and small sample size requirements of AMS. |
---|---|
AbstractList | Accelerator mass spectrometry (AMS) is used to determine the amount of carcinogen covalently bound to mouse liver DNA (DNA adduct) following very low-level exposure to a {sup 14}C-labeled carcinogen. AMS is a highly sensitive method for counting long-lived but rare cosmogenic isotopes. While AMS is a tool of importance in the earth sciences, it has not been applied in biomedical research. The ability of AMS to assay rare isotope concentrations ({sup 10}Be, {sup 14}C, {sup 26}Al, {sup 41}Ca, and {sup 129}I) in microgram amounts suggests that extension to the biomedical sciences is a natural and potentially powerful application of the technology. In this study, the relationship between exposure to low levels of 2-amino-3,8-dimethyl(2-{sup 14}C)imidazo(4,5-f)quinoxaline and formation of DNA adducts is examined to establish the dynamic range of the technique and the potential sensitivity for biological measurements, as well as to evaluate the relationship between DNA adducts and low-dose carcinogen exposure. Formation of adducts is linearly dependent on dose down to an exposure of 500 ng per kg of body weight. With the present measurements, the authors demonstrate at least 1 order of magnitude improvement over the best adduct detection sensitivity reported to data and 3-5 orders of magnitude improvement over other methods used for adduct measurement. Expanded applications involving human subjects, including clinical applications, are now expected because of the great detection sensitivity and small sample size requirements of AMS. Accelerator mass spectrometry (AMS) is used to determine the amount of carcinogen covalently bound to mouse liver DNA (DNA adduct) following very low-level exposure to a 14C-labeled carcinogen. AMS is a highly sensitive method for counting long-lived but rare cosmogenic isotopes. While AMS is a tool of importance in the earth sciences, it has not been applied in biomedical research. The ability of AMS to assay rare isotope concentrations (10Be, 14C, 26Al, 41Ca, and 129I) in microgram amounts suggests that extension to the biomedical sciences is a natural and potentially powerful application of the technology. In this study, the relationship between exposure to low levels of 2-amino-3,8-dimethyl[2-14C]imidazo[4,5-f]quinoxaline and formation of DNA adducts is examined to establish the dynamic range of the technique and the potential sensitivity for biological measurements, as well as to evaluate the relationship between DNA adducts and low-dose carcinogen exposure. Instrument reproducibility in this study is 2%; sensitivity is 1 adduct per 10(11) nucleotides. Formation of adducts is linearly dependent on dose down to an exposure of 500 ng per kg of body weight. With the present measurements, we demonstrate at least 1 order of magnitude improvement over the best adduct detection sensitivity reported to date and 3-5 orders of magnitude improvement over other methods used for adduct measurement. An additional improvement of 2 orders of magnitude in sensitivity is suggested by preliminary experiments to develop bacterial hosts depleted in radiocarbon. Expanded applications involving human subjects, including clinical applications, are now expected because of the great detection sensitivity and small sample size requirements of AMS. Accelerator mass spectrometry (AMS) is used to determine the amount of carcinogen covalently bound to mouse liver DNA (DNA adduct) following very low-level exposure to a14C-labeled carcinogen. AMS is a highly sensitive method for counting long-lived but rare cosmogenic isotopes. While AMS is a tool of importance in the earth sciences, it has not been applied in biomedical research. The ability of AMS to assay rare isotope concentrations (10Be,14C,26Al,41Ca, and129I) in microgram amounts suggests that extension to the biomedical sciences is a natural and potentially powerful application of the technology. In this study, the relationship between exposure to low levels of 2-amino-3,8-dimethyl[2-14C]imidazo[4,5-f]quinoxaline and formation of DNA adducts is examined to establish the dynamic range of the technique and the potential sensitivity for biological measurements, as well as to evaluate the relationship between DNA adducts and low-dose carcinogen exposure. Instrument reproducibility in this study is 2%; sensitivity is 1 adduct per 1011nucleotides. Formation of adducts is linearly dependent on dose down to an exposure of 500 ng per kg of body weight. With the present measurements, we demonstrate at least 1 order of magnitude improvement over the best adduct detection sensitivity reported to date and 3-5 orders of magnitude improvement over other methods used for adduct measurement. An additional improvement of 2 orders of magnitude in sensitivity is suggested by preliminary experiments to develop bacterial hosts depleted in radiocarbon. Expanded applications involving human subjects, including clinical applications, are now expected because of the great detection sensitivity and small sample size requirements of AMS. Accelerator mass spectrometry (AMS) is used to determine the amount of carcinogen covalently bound to mouse liver DNA (DNA adduct) following very low-level exposure to a 14C-labeled carcinogen. AMS is a highly sensitive method for counting long-lived but rare cosmogenic isotopes. While AMS is a tool of importance in the earth sciences, it has not been applied in biomedical research. The ability of AMS to assay rare isotope concentrations (10Be, 14C, 26Al, 41Ca, and 129I) in microgram amounts suggests that extension to the biomedical sciences is a natural and potentially powerful application of the technology. In this study, the relationship between exposure to low levels of 2-amino-3,8-dimethyl[2-14C]imidazo[4,5-f]quinoxaline and formation of DNA adducts is examined to establish the dynamic range of the technique and the potential sensitivity for biological measurements, as well as to evaluate the relationship between DNA adducts and low-dose carcinogen exposure. Instrument reproducibility in this study is 2%; sensitivity is 1 adduct per 10(11) nucleotides. Formation of adducts is linearly dependent on dose down to an exposure of 500 ng per kg of body weight. With the present measurements, we demonstrate at least 1 order of magnitude improvement over the best adduct detection sensitivity reported to date and 3-5 orders of magnitude improvement over other methods used for adduct measurement. An additional improvement of 2 orders of magnitude in sensitivity is suggested by preliminary experiments to develop bacterial hosts depleted in radiocarbon. Expanded applications involving human subjects, including clinical applications, are now expected because of the great detection sensitivity and small sample size requirements of AMS.Accelerator mass spectrometry (AMS) is used to determine the amount of carcinogen covalently bound to mouse liver DNA (DNA adduct) following very low-level exposure to a 14C-labeled carcinogen. AMS is a highly sensitive method for counting long-lived but rare cosmogenic isotopes. While AMS is a tool of importance in the earth sciences, it has not been applied in biomedical research. The ability of AMS to assay rare isotope concentrations (10Be, 14C, 26Al, 41Ca, and 129I) in microgram amounts suggests that extension to the biomedical sciences is a natural and potentially powerful application of the technology. In this study, the relationship between exposure to low levels of 2-amino-3,8-dimethyl[2-14C]imidazo[4,5-f]quinoxaline and formation of DNA adducts is examined to establish the dynamic range of the technique and the potential sensitivity for biological measurements, as well as to evaluate the relationship between DNA adducts and low-dose carcinogen exposure. Instrument reproducibility in this study is 2%; sensitivity is 1 adduct per 10(11) nucleotides. Formation of adducts is linearly dependent on dose down to an exposure of 500 ng per kg of body weight. With the present measurements, we demonstrate at least 1 order of magnitude improvement over the best adduct detection sensitivity reported to date and 3-5 orders of magnitude improvement over other methods used for adduct measurement. An additional improvement of 2 orders of magnitude in sensitivity is suggested by preliminary experiments to develop bacterial hosts depleted in radiocarbon. Expanded applications involving human subjects, including clinical applications, are now expected because of the great detection sensitivity and small sample size requirements of AMS. Accelerator mass spectrometry (AMS) is used to determine the amount of carcinogen covalently bound to mouse liver DNA (DNA adduct) following very low-level exposure to a super(14)C-labeled carcinogen. AMS is a highly sensitive method for counting long-lived but rare cosmogenic isotopes. While AMS is a tool of importance in the earth sciences, it has not been applied in biomedical research. The ability of AMS to assay rare isotope concentrations ( super(10)Be, super(14)C, super(26)Al, super(41)Ca, and super(129)I) in microgram amounts suggests that extension to the biomedical sciences is a natural and potentially powerful application of the technology. In this study, the relationship between exposure to low levels of 2-amino-3,8-dimethyl(2- super(14)C)imidazo(4,5-f)quinoxaline and formation of DNA adducts is examined to establish the dynamic range of the technique and the potential sensitivity for biological measurements, as well as to evaluate the relationship between DNA adduct and low-dose carcinogen exposure. |
Author | Proctor, I. D. Gledhill, B. L. Felton, J. S. Caffee, M. W. Nelson, D. E. Finkel, R. C. Vogel, J. S. Southon, J. R. Turteltaub, K. W. Davis, J. C. |
AuthorAffiliation | Biomedical Sciences Division, University of California, Livermore 94550 |
AuthorAffiliation_xml | – name: Biomedical Sciences Division, University of California, Livermore 94550 |
Author_xml | – sequence: 1 givenname: K. W. surname: Turteltaub fullname: Turteltaub, K. W. – sequence: 2 givenname: J. S. surname: Felton fullname: Felton, J. S. – sequence: 3 givenname: B. L. surname: Gledhill fullname: Gledhill, B. L. – sequence: 4 givenname: J. S. surname: Vogel fullname: Vogel, J. S. – sequence: 5 givenname: J. R. surname: Southon fullname: Southon, J. R. – sequence: 6 givenname: M. W. surname: Caffee fullname: Caffee, M. W. – sequence: 7 givenname: R. C. surname: Finkel fullname: Finkel, R. C. – sequence: 8 givenname: D. E. surname: Nelson fullname: Nelson, D. E. – sequence: 9 givenname: I. D. surname: Proctor fullname: Proctor, I. D. – sequence: 10 givenname: J. C. surname: Davis fullname: Davis, J. C. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19545497$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/2371271$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/6151460$$D View this record in Osti.gov |
BookMark | eNqFkstuEzEUhkeoqKSFNRtAFhKwmtSesccexCZNC0UKIHFZWx7nTOJqYk9tJ23ehYfFaULUIgErH_l8_7kfZQfWWciypwQPCeblSW9VGAo-JHTICiEeZAOCa5JXtMYH2QDjgueCFvRRdhTCJca4ZgIfZodFyUnBySD7OdIaOvAqOo8-qRDQtx509G4B0a-RsejUJHtqtOrQmQvm9v8t-gqdisbZMDc9OoV4DWDRxF3nE1hBh85veheWHpCyUzR2K9WBjSmUnRo7Q65FFxDBO73WndFotDAW0Fh5baybgQ0oOnT2efQ4e9iqLsCT3Xuc_Xh__n18kU--fPg4Hk1yzTiLObQAFJpKVbhoKJkqghUuWyymDauJAtbUlGJaNpS1tSYgqnpKkwVYNS0nujzO3m3j9ssm9apTrV51svdmofxaOmXkfY81czlzK8loiUWSv9zKXYhGBm0i6Ll21qZByoowQiucoNe7HN5dLSFEuTAhjb5TFtwySF4LLjjl_wUJEyUuqzKBz-9WvS93t9vkf7Xzq5C213pltQl7jNSMMlpvErItp70LwUMrUwe3y029mk4SLDenJjenJgWXhMrNqSXdyR-6fei_Kl7sKto4ftP3gDf_BGS77LoINzGRz7bkZUiXe6d3xjDH5S-dqfvE |
CODEN | PNASA6 |
CitedBy_id | crossref_primary_10_1016_S0027_5107_97_00049_3 crossref_primary_10_14494_jnrs2000_2_R9 crossref_primary_10_1002_tox_20295 crossref_primary_10_1016_j_taap_2005_04_022 crossref_primary_10_1002_jcph_569 crossref_primary_10_1039_c3an00077j crossref_primary_10_1111_j_1600_0773_1992_tb00460_x crossref_primary_10_1073_pnas_071047998 crossref_primary_10_1002_mnfr_200400076 crossref_primary_10_3109_10408449409021608 crossref_primary_10_1006_taap_1999_8722 crossref_primary_10_1016_0165_9936_92_87076_V crossref_primary_10_15407_scin6_01_017 crossref_primary_10_1093_toxsci_kfn176 crossref_primary_10_1093_toxsci_kfp232 crossref_primary_10_1093_toxsci_kfj016 crossref_primary_10_1177_074823370001600312 crossref_primary_10_4155_bio_2019_0119 crossref_primary_10_1103_RevModPhys_95_035006 crossref_primary_10_1079_NRR200129 crossref_primary_10_1016_j_jpba_2021_114152 crossref_primary_10_1016_j_yrtph_2015_06_015 crossref_primary_10_1016_S0378_4274_98_00344_0 crossref_primary_10_1016_S0731_7085_00_00397_6 crossref_primary_10_1016_j_yrtph_2004_01_003 crossref_primary_10_1017_S0033822200053273 crossref_primary_10_1021_tx2004536 crossref_primary_10_1177_01926233211064180 crossref_primary_10_1111_j_1753_4887_2004_tb00008_x crossref_primary_10_1081_DMR_120005665 crossref_primary_10_1016_S0955_2863_97_00080_6 crossref_primary_10_1177_026119291804600603 crossref_primary_10_1255_ejms_1078 crossref_primary_10_1021_acs_analchem_6b02054 crossref_primary_10_1124_dmd_104_000422 crossref_primary_10_1016_j_nimb_2015_02_008 crossref_primary_10_1021_acs_chemrestox_5b00495 crossref_primary_10_1002_mas_20059 crossref_primary_10_1021_tx200135s crossref_primary_10_1021_tx700125p crossref_primary_10_1016_S0278_6915_98_00003_9 crossref_primary_10_1007_s002040050050 crossref_primary_10_1007_s00228_013_1528_2 crossref_primary_10_1128_AAC_03300_14 crossref_primary_10_1016_j_fct_2016_09_029 crossref_primary_10_1021_acs_analchem_4c04874 crossref_primary_10_1016_S0009_2797_03_00022_X crossref_primary_10_1017_S0033822200058021 crossref_primary_10_1021_bi901059k crossref_primary_10_1111_cts_12390 crossref_primary_10_1016_j_ijms_2013_05_023 crossref_primary_10_2144_05386SU04 crossref_primary_10_4155_bio_11_276 crossref_primary_10_1016_j_nimb_2012_08_054 crossref_primary_10_1016_j_nimb_2004_04_138 crossref_primary_10_1002_jms_1190301002 crossref_primary_10_1017_RDC_2024_47 crossref_primary_10_1038_s41467_021_26642_9 crossref_primary_10_1080_10506890009411512 crossref_primary_10_1517_14740338_1_3_253 crossref_primary_10_1016_j_fct_2007_08_027 crossref_primary_10_1016_S0304_3835_06_80035_2 crossref_primary_10_1016_j_nimb_2015_04_047 crossref_primary_10_4155_bio_09_188 crossref_primary_10_1016_S0009_2797_97_00061_6 crossref_primary_10_4155_bio_12_242 crossref_primary_10_1016_j_nimb_2016_10_038 crossref_primary_10_1002_mas_1280110602 crossref_primary_10_1016_j_ijms_2018_08_003 crossref_primary_10_1016_0168_1176_92_85077_D crossref_primary_10_1038_nrd1037 crossref_primary_10_3390_foods11182828 crossref_primary_10_1016_j_nimb_2007_01_215 crossref_primary_10_1016_j_addr_2010_10_009 crossref_primary_10_1080_17576180_2025_2460391 crossref_primary_10_1016_j_mrgentox_2010_08_021 crossref_primary_10_4155_bio_11_285 crossref_primary_10_1021_ac971383v crossref_primary_10_1080_026520300283360 crossref_primary_10_1016_S0168_583X_00_00230_5 crossref_primary_10_1016_j_mrgentox_2009_06_001 crossref_primary_10_1016_j_jchromb_2003_10_053 crossref_primary_10_1002_jcb_240531019 crossref_primary_10_1021_nl302412f crossref_primary_10_1021_acs_accounts_9b00054 crossref_primary_10_1177_074823379300900406 crossref_primary_10_1006_abio_1998_2891 crossref_primary_10_1002__SICI_1097_0215_19990209_80_4_539__AID_IJC10_3_0_CO_2_C crossref_primary_10_1021_jf100113c crossref_primary_10_1007_BF02900404 crossref_primary_10_1073_pnas_040575997 crossref_primary_10_1016_S0300_483X_02_00250_0 crossref_primary_10_1006_taap_1997_8248 crossref_primary_10_1111_j_1349_7006_1993_tb02058_x crossref_primary_10_1016_j_tips_2004_06_009 crossref_primary_10_1177_0091270005280051 crossref_primary_10_1158_0008_5472_CAN_06_1573 crossref_primary_10_1293_tox_14_213 crossref_primary_10_4155_fso_15_74 crossref_primary_10_1016_S0304_3835_99_00116_0 crossref_primary_10_1007_s00216_007_1306_z crossref_primary_10_1002__SICI_1097_0231_19990228_13_4_285__AID_RCM469_3_0_CO_2_R crossref_primary_10_1002__SICI_1098_2280_2000_35_1_57__AID_EM8_3_0_CO_2_7 crossref_primary_10_1002_mnfr_201200226 crossref_primary_10_1080_17425247_2016_1227786 crossref_primary_10_1016_S0890_6238_99_00011_8 crossref_primary_10_4155_bio_10_14 crossref_primary_10_1002_jps_21160 crossref_primary_10_1006_bbrc_2000_4161 crossref_primary_10_1016_S0168_583X_00_00235_4 crossref_primary_10_1016_S1383_5742_01_00059_X crossref_primary_10_1021_ja5100542 crossref_primary_10_1093_carcin_20_3_353 crossref_primary_10_4155_bio_12_297 crossref_primary_10_1186_s41021_021_00200_7 crossref_primary_10_1021_ac103038s crossref_primary_10_1002_rcm_5149 crossref_primary_10_1017_S0033822200063529 crossref_primary_10_1002_ijc_25814 crossref_primary_10_1373_clinchem_2005_049650 crossref_primary_10_3109_10408444_2013_835787 |
ContentType | Journal Article |
Copyright | 1991 INIST-CNRS |
Copyright_xml | – notice: 1991 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TM 7X8 OTOTI 5PM |
DOI | 10.1073/pnas.87.14.5288 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nucleic Acids Abstracts MEDLINE - Academic OSTI.GOV PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic Nucleic Acids Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) |
EISSN | 1091-6490 |
EndPage | 5292 |
ExternalDocumentID | PMC54308 6151460 2371271 19545497 10_1073_pnas_87_14_5288 87_14_5288 2355070 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, U.S. Gov't, P.H.S Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NIEHS NIH HHS grantid: 222Y-01-ES-70158 – fundername: NCI NIH HHS grantid: CA40811 |
GroupedDBID | --- -DZ -~X .55 .GJ 0R~ 123 29P 2AX 2FS 2WC 3O- 4.4 53G 5RE 5VS 85S AACGO AAFWJ AANCE ABBHK ABOCM ABPLY ABPPZ ABTLG ABXSQ ABZEH ACGOD ACHIC ACIWK ACNCT ACPRK ADQXQ ADULT ADXHL AENEX AEUPB AEXZC AFFNX AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS AQVQM AS~ CS3 D0L DCCCD DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 HGD HH5 HQ3 HTVGU HYE IPSME JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST KQ8 L7B LU7 MVM N9A NEJ N~3 O9- OK1 P-O PNE PQQKQ R.V RHI RNA RNS RPM RXW SA0 SJN TN5 UKR VOH W8F WH7 WHG WOQ WOW X7M XSW Y6R YKV YSK ZCA ZCG ~02 ~KM - 02 08R 0R 1AW 55 AAPBV ABFLS ABPTK ADACO ADZLD AFDAS AJYGW AS ASUFR DNJUQ DOOOF DWIUU DZ F20 GJ JSODD KM OHM PQEST RHF VQA X XFK XHC ZA5 692 6TJ 79B AAYJJ AAYXX ACKIV AFHIN AFQQW BKOMP CITATION NHB TAE YBH IQODW CGR CUY CVF ECM EIF NPM VXZ YIF YIN 7TM 7X8 OTOTI 5PM |
ID | FETCH-LOGICAL-c575t-efee4eb6a602b41da10a03f08db591ae5b944043b45f9c1e869d4f9ce0abf71c3 |
ISSN | 0027-8424 |
IngestDate | Thu Aug 21 18:31:00 EDT 2025 Thu May 18 18:17:18 EDT 2023 Fri Jul 11 00:05:10 EDT 2025 Fri Jul 11 10:57:35 EDT 2025 Wed Feb 19 02:35:19 EST 2025 Mon Jul 21 09:15:34 EDT 2025 Thu Apr 24 23:02:02 EDT 2025 Tue Jul 01 01:22:04 EDT 2025 Wed Nov 11 00:29:26 EST 2020 Thu May 30 08:53:08 EDT 2019 Thu May 29 08:43:02 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 14 |
Keywords | Quinoxaline derivatives Radiolabelling Liver Rodentia Cytotoxicity Carcinogen Vertebrata Mammalia Methylosinus trichosporium Mouse DNA Molecular association Covalent bond Bacteria Mass spectrometry Molecular adduct Physicochemical properties Quantitative analysis |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c575t-efee4eb6a602b41da10a03f08db591ae5b944043b45f9c1e869d4f9ce0abf71c3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 2371271 |
PQID | 15830363 |
PQPubID | 23462 |
PageCount | 5 |
ParticipantIDs | crossref_citationtrail_10_1073_pnas_87_14_5288 pnas_primary_87_14_5288_fulltext pascalfrancis_primary_19545497 jstor_primary_2355070 pnas_primary_87_14_5288 pubmedcentral_primary_oai_pubmedcentral_nih_gov_54308 osti_scitechconnect_6151460 proquest_miscellaneous_79878747 proquest_miscellaneous_15830363 crossref_primary_10_1073_pnas_87_14_5288 pubmed_primary_2371271 |
ProviderPackageCode | RNA PNE CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1990-07-01 |
PublicationDateYYYYMMDD | 1990-07-01 |
PublicationDate_xml | – month: 07 year: 1990 text: 1990-07-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Washington, DC |
PublicationPlace_xml | – name: Washington, DC – name: United States |
PublicationTitle | Proceedings of the National Academy of Sciences - PNAS |
PublicationTitleAlternate | Proc Natl Acad Sci U S A |
PublicationYear | 1990 |
Publisher | National Academy of Sciences of the United States of America National Acad Sciences |
Publisher_xml | – name: National Academy of Sciences of the United States of America – name: National Acad Sciences |
SSID | ssj0009580 |
Score | 1.7432758 |
Snippet | Accelerator mass spectrometry (AMS) is used to determine the amount of carcinogen covalently bound to mouse liver DNA (DNA adduct) following very low-level... |
SourceID | pubmedcentral osti proquest pubmed pascalfrancis crossref pnas jstor |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 5288 |
SubjectTerms | 550201 - Biochemistry- Tracer Techniques ADDUCTS AMINES Analytical biochemistry: general aspects, technics, instrumentation Analytical, structural and metabolic biochemistry ANIMALS BACTERIA BASIC BIOLOGICAL SCIENCES Biological and medical sciences BODY Body weight CARBON 14 COMPOUNDS Carbon Radioisotopes CARCINOGENS Carcinogens - metabolism CHRONIC EXPOSURE DIGESTIVE SYSTEM Dioxins - metabolism DNA DNA - isolation & purification DNA - metabolism DNA ADDUCTS Dosage Dose-Response Relationship, Drug DOSE-RESPONSE RELATIONSHIPS Fundamental and applied biological sciences. Psychology GLANDS Isotopes Kinetics LABELLED COMPOUNDS LIVER Liver - metabolism Male MAMMALS MAN MASS SPECTROMETERS Mass Spectrometry - methods MASS SPECTROSCOPY MEASURING INSTRUMENTS MICE Mice, Inbred C57BL MICROORGANISMS Nucleotides ORGANIC COMPOUNDS ORGANS Phosphorus Radioisotopes Polychlorinated Dibenzodioxins - metabolism POLYCYCLIC AROMATIC AMINES PRIMATES Quinoxalines - metabolism Radiocarbon RODENTS SENSITIVITY SPECTROMETERS SPECTROSCOPY VERTEBRATES |
Title | Accelerator Mass Spectrometry in Biomedical Dosimetry: Relationship Between Low-Level Exposure and Covalent Binding of Heterocyclic Amine Carcinogens to DNA |
URI | https://www.jstor.org/stable/2355070 http://www.pnas.org/content/87/14/5288.abstract https://www.ncbi.nlm.nih.gov/pubmed/2371271 https://www.proquest.com/docview/15830363 https://www.proquest.com/docview/79878747 https://www.osti.gov/biblio/6151460 https://pubmed.ncbi.nlm.nih.gov/PMC54308 |
Volume | 87 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGENJeEIONlcHwAw9DUUo-nC_eKmCbAFWT2GBvkeM6olKXTE0qBH8L_ykv3NlO6pZVAl6qKHFjR3c_39m--x0hL1Lw2GQoAEgeFy7jnnSLOMUz1yTgqfA5nyi2z3F8dsneX0VXW1u_rKilRVsMxY9b80r-R6pwD-SKWbL_INn-pXADrkG-8AsSht-_kvFICLAa6qDcuQYv2FF5k0hA0M5VPp9OrtcnMXUzVfdxD2DehcDZoVqz-ps7wxgipP2vm-5kQdQwZIwYKKY6A0a5lyCOWnwXSJHNr9FTFViUqKphrIoz4u14ZPu9572dbLqohHG3DTlaJrWYmaZxXOd8vCyR_MH54lws5q2ctXxR9EE_zifnRGJV7H5PwfnonM7kBE847FafaxO5q_c3fLCNfSxsa9OD68H0w7Cn9ADMLNOJ2EOpZ3FwgtyY6Tqk3TRv7LpRZ2ZN2lGgKwv-YU1g-sMSyBVvhmkCNmW43hIkdnOtlCsIEz_QxWRWSb3XjG0fApkmsOrK8YV3yN0AEIPlN06vfIsxOtX5U-b7Ol6qJHy1NqIdcs90v-Jc6fhacDVqMBYY88sbULdS12tBLl94y23rqvXwYMvfunhA7puFEh1prd8lW7J6SHY7ydBjw5f-8hH5acGAIgyoDQM6regSBrSHwWtqg4AaENAeBLQDAQUQ0A4E1ICA1iW1QUAVCKgFAtrWFECwRy5P3l28OXNN0RFXwMqldWUpJZNFzGMvKJg_4b7HvbD00kkRZT6XUZEhpWZYsKjMhC_TOJswuJIeL8rEF-E-2a7qSh4Q6mc8BO9BlGXCWTIpM7W4SmSAmwBhygdk2EkrF4aRHwvDzHIVGZKEOYooX2rKgBz3f7jRZDSbm-4p8fftghCZC70BOUR1yMG_RpJogdF0os1xXcNieHq0oiXLXjJYabEsGZDHqqPuvt0h3fAkL00Y24A875QtByOGJ5O8kvWiyf0oRVc63NwiyVJwLRgMYF8rp_VhSvUHJFrR2v458uevPqmmXxWPfsRCL32y8YsOyc5yPnpKttv5Qj6DFUhbHCmk_gb6_zoT |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Accelerator+mass+spectrometry+in+biomedical+dosimetry%3A+relationship+between+low-level+exposure+and+covalent+binding+of+heterocyclic+amine+carcinogens+to+DNA&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=K+W+Turteltaub&rft.au=J+S+Felton&rft.au=B+L+Gledhill&rft.au=J+S+Vogel&rft.date=1990-07-01&rft.pub=National+Acad+Sciences&rft.issn=0027-8424&rft.eissn=1091-6490&rft.volume=87&rft.issue=14&rft.spage=5288&rft_id=info:doi/10.1073%2Fpnas.87.14.5288&rft_id=info%3Apmid%2F2371271&rft.externalDBID=n%2Fa&rft.externalDocID=87_14_5288 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F87%2F14.cover.gif |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F87%2F14.cover.gif |